On Friday, Pinnacle West Capital Corporation (NYSE:PNW)’s shares inclined 1.07% to $60.32.
Pinnacle West Capital Corporation (PNW) Board of Directors declared a quarterly dividend of $0.595 per share of common stock, payable on September 1, 2015, to shareholders of record on August 3, 2015.
Pinnacle West Capital Corporation, through its partner, Arizona Public Service Company, provides retail and wholesale electric services primarily in the State of Arizona. It generates, transmits, and distributes electricity using coal, nuclear, gas, oil, and solar resources. The company serves about 1.2 million customers. It owns or leases about 6,426 megawatts of regulated generation capacity. The company was founded in 1920 and is headquartered in Phoenix, Arizona.
BioMarin Pharmaceutical Inc.(NASDAQ:BMRN)’s shares gained 1.10% to $141.67.
BioMarin Pharmaceutical Inc. (BMRN) recently declared the U.S. Food and Drug Administration (FDA) has accepted for review the submission of a New Drug Application (NDA) for drisapersen for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping, and the Prescription Drug User Fee Act (PDUFA) aim date for a decision is December 27, 2015. The FDA has granted drisapersen Priority Review status, which is designated to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.
In the FDA’s filing communication, the Agency informed the company that it is presently planning to hold an advisory committee meeting to talk about the application. No date has been set for this meeting. Drisapersen formerly has been granted Orphan and Fast Track status, in addition to Breakthrough Therapy designations by the FDA. The U.S. filing is based on three randomized placebo-controlled trials and two long-term open-label studies of more than 300 patients in which some boys have been treated for more than three years.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
At the end of Friday’s trade, Vulcan Materials Company(NYSE:VMC)‘s shares surged 5.17% to $90.36.
The Board of Directors of Vulcan Materials Company (VMC) recently declared a quarterly cash dividend of ten cents per share on its common stock. The dividend will be payable on September 10, 2015, to shareholders of record at the close of business on August 25, 2015.
Vulcan Materials Company produces and sells construction aggregates, asphalt mix, and ready-mixed concrete primarily in the United States. It operates through four segments: Aggregates, Asphalt Mix, Concrete, and Calcium. The Aggregates segment offers crushed stone, sand and gravel, sand, and other aggregates, in addition to related products and services.
Fulton Financial Corp(NASDAQ:FULT), ended its Friday’s trading session with 1.61% gain, and closed at $13.23.
The Board of Directors of Fulton Financial Corporation (NASDAQ: FULT) has declared a quarterly cash dividend of nine cents per share on its common stock, payable on July 15, 2015 to shareholders of record as of July 1, 2015.
Fulton Financial Corporation, a $17.4 billion Lancaster, Pa.-based financial holding company, has about 3,700 employees and operates more than 240 branches in Pennsylvania, Maryland, Delaware, New Jersey and Virginia through six partner banks.
Fulton Financial Corporation operates as a multi-bank financial holding company that provides a range of banking and financial services to businesses and consumers. It offers personal banking services that comprise various checking account and savings deposit products, certificates of deposit, and individual retirement accounts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
